Aktienanalyse zu Abivax SA (ABVX)ABVXAbivax SA

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others. It operates in the Healthcare sector.

Abivax SA is currently not a strong buy due to its low RSI of 30.077, indicating oversold conditions, and a significant 34.10% year-to-date decline in stock price. However, the recent funding of $920 million for its drug launch provides a financial cushion and potential for future growth. The average analyst price target is around $151, suggesting a potential upside from the current price of $88.15, but the risks remain high with a negative P/E ratio of -14.36 and a recent earnings miss of 58.33%.